You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
According to the Los Angeles Times, National Institutes of Health officials are concerned about the possible side effect reported by a COVID-19 vaccine trial.
After a pause, AstraZeneca has resumed its COVID-19 vaccine clinical trial in the UK, according to NPR.
Planned and ongoing studies will use standardized plasma protein profiling workflows to discover biomarkers for a range of conditions.
The Washington Post reports AstraZeneca's pausing of its candidate vaccine trial indicates the science is being followed.
According to Reuters, AstraZeneca has begun enrolling participants into a late-stage study of its candidate SARS-CoV-2 vaccine.
The firms will initially use RenalytixAI's KidneyIntelX platform to help improve outcomes for patients with chronic kidney disease and its complications.
The New York Times reports two additional investigational vaccines appear to generate an immune response against SARS-CoV-2.
In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors.
ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.